Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29778052 | 1.00 | PKM (0.45) | PKMLMNAL3MBTL1AAK1GPR84 | |
| SCHEMBL7268338 | 0.84 | IDO1 (0.48) | LMNAKMT2AIDO1EP300KAT8 | |
| SCHEMBL10110679 | 0.82 | IDO1 (0.32) | IDO1EP300KAT8CA12CA1 | |
| SCHEMBL7262960 | 0.81 | IDO1 (0.45) | PKMNPSR1MEN1KMT2AIDO1 | |
| SCHEMBL29977674 | 0.81 | ALOX5AP (0.34) | PKMGPR84SLC22A12MEN1KMT2A | |
| SCHEMBL12599055 | 0.81 | IDO1 (0.55) | PKML3MBTL1MEN1KMT2AIDO1 | |
| SCHEMBL15180209 | 0.79 | KMT2A (0.47) | LMNAL3MBTL1NPSR1MEN1KMT2A | |
| SCHEMBL17977218 | 0.79 | LDHA (0.47) | PKMLMNAL3MBTL1NPSR1MEN1 | |
| SCHEMBL29862928 | 0.79 | KMT2A (0.47) | LMNAL3MBTL1NPSR1MEN1KMT2A | |
| SCHEMBL28403258 | 0.78 | CA12 (0.36) | CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PROMIDIS S.R.L. (IT) | 2024-04-04 | — | — | US | disclosed |
| EP-4288431-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022167682-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-08-11 | — | — | WO | disclosed |
| EP-4039685-A1 | AZABICYCLIC SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2022-08-10 | — | — | EP | disclosed |
| EP-2257296-B1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575176-B2 | Heteroaromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575176-B2 | Heteroaromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| EP-2257296-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009139948-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090214444-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090214444-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| EP-0001290-B1 | SUBSTITUTED 2,3-DIHYDROBENZ-(D)-ISOTHIAZOLE-1,1-DIOXIDES AND 2,3-DIHYDRONAPHTHO-(1,8-DE)-1,2-THIAZINE-1,1-DIOXIDES | POLAROID CORPORATION (US) | 1984-06-27 | — | — | EP | disclosed |
| US-4359574-A | Thiazine-1,1-dioxide and isothiazole-1,1-dioxide derivatives | POLAROID CORPORATION (US) | 1982-11-16 | — | — | US | disclosed |
| US-4259498-A | Process for preparing benzisothiazole-1,1-dioxide and naphtho-1,2-thiazine-1,1-dioxide compounds | POLAROID CORPORATION (US) | 1981-03-31 | — | — | US | disclosed |
| US-4195180-A | Sulfam (na) phthaleins | POLAROID CORPORATION (US) | 1980-03-25 | — | — | US | disclosed |
| US-4191689-A | Benzisothiazole-1,1-dioxide and naphtho-1,2-thiazine-1,1-dioxide compounds | POLAROID CORPORATION (US) | 1980-03-04 | — | — | US | disclosed |
| EP-0001290-A1 | Substituted 2,3-dihydrobenz-(d)-isothiazole-1,1-dioxides and 2,3-dihydronaphtho-(1,8-de)-1,2-thiazine-1,1-dioxides | POLAROID CORPORATION (US) | 1979-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PTPN22, PTPN2, PTPN5 | PKM 4626/4885LMNA 4847/4885L3MBTL1 3345/4885 |
| US-20090214444-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCNN1B | PKM 3673/4885LMNA 956/4885L3MBTL1 4580/4885 |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCNN1B | PKM 3673/4885LMNA 956/4885L3MBTL1 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.